Diabetes
| T2D, Heart & Renal
Diabetes
T2D, Heart & Renal
The Combined Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists on the Risk of Cardiovascular Events among Patients with Type 2 Diabetes
book_2
Source:
ADA 2023 - Oral Presentation
calendar_today
Published on Medfyle:
July 2023
import_contacts
4
min
In this medfyle
In this population-based study using real-world data, combined use of GLP-1 RAs and SGLT2is was associated with a decreased risk of MACE and serious renal events vs. monotherapy with either drug class.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This content is intended for an international audience of non-UK healthcare professionals. The content is made available through a licensing agreement between Infomedica and the American Diabetes Association (ADA).
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, Medfyle, or the ADA.
©2023 Infomedica-Medfyle. All rights reserved.
